Exelixis, Inc.
NASDAQ Global SelectRecent
price
P/E
ratio
div
yld
- -
ROIC.AI
Capital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- Similar Companies
- Business
- Exelixis, Inc. (Nasdaq: EXEL) is an oncology-focused biotechnology company that discovers, develops, and commercializes new medicines for difficult-to-treat cancers. The company offers CABOMETYX (cabozantinib) tablets for advanced renal cell carcinoma, hepatocellular carcinoma, and previously treated advanced neuroendocrine tumors; COMETRIQ (cabozantinib) capsules for metastatic medullary thyroid cancer; and COTELLIC (cobimetinib), partnered with Roche/Genentech for advanced melanoma. Exelixis advances a diversified pipeline of small-molecule therapeutics and biotherapeutics, including bispecific antibodies, antibody-drug conjugates, next-generation kinase inhibitors such as zanzalintinib in phase 3 trials for renal cell carcinoma, hepatocellular carcinoma, and squamous cell carcinoma of the head and neck, and early-stage programs like XL309 targeting PARP inhibitors. Founded in 1994 and headquartered in Alameda, California, the company conducts global operations through strategic partnerships with Bristol Myers Squibb, Merck, Takeda Pharmaceutical, and others to expand development and commercialization reach. Recent developments include U.S. FDA approval of a new CABOMETYX indication for previously treated advanced neuroendocrine tumors; authorization of a $500 million stock repurchase program in February 2025 following completion of a prior $500 million program from August 2024, with over $1.2 billion returned to shareholders since March 2023; plans to initiate phase 3 trials for zanzalintinib in neuroendocrine tumors and two Merck-collaborated renal cell carcinoma studies in 2025; and ongoing enrollment in XL309 monotherapy and combination trials for PARP-refractory tumors.
Company News
Why Exelixis (EXEL) is a Top Growth Stock for the Long-Term
Why Exelixis (EXEL) is Poised to Beat Earnings Estimates Again
Kuehn Law Encourages Investors of EXELIXIS, Inc. to Contact Law Firm
Kuehn Law Encourages Investors of EXELIXIS, Inc. to Contact Law Firm
Exelixis (NASDAQ:EXEL) Hits New 1-Year High – Here’s What Happened
Here's Why Exelixis (EXEL) is a Strong Value Stock
Exelixis Shares Rising on CABOMETYX Revenue
Exelixis (EXEL) is a Top-Ranked Growth Stock: Should You Buy?
Could Zanzalintinib's FDA Delay Affect Exelixis' Growth Plans?
Here's Why Exelixis (EXEL) is a Strong Momentum Stock
Why Exelixis (EXEL) is a Top Value Stock for the Long-Term
Exelixis Eyes Oncology Deals, Readies Zanzalintinib Launch as Cabozantinib Tops $3B
Exelixis, Inc. (EXEL) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
Exelixis Eyes Zanza Launch as CABOMETYX Growth Faces NET Ramp Hurdle
Here's Why Exelixis (EXEL) is a Strong Growth Stock
Integrated Wealth Concepts LLC Has $3.19 Million Stock Holdings in Exelixis, Inc. $EXEL
Exelixis Eyes CABOMETYX Growth, Zanzalintinib Catalysts Across Cancer Franchises
Exelixis: The FDA Delay Costs Less Than The Market Thinks
Exelixis Stock Slips as FDA Delays Cancer Drug Review, Analyst Weighs In
U.S. FDA extends review of Exelixis' cancer drug